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Abstract 1 
Background Non-steroidal anti-inflammatory drugs and vitamin D derivatives can target signaling 2 
pathways activated in Basal Cell Carcinoma (BCC). 3 
Objective We investigated the efficacy of topically applied diclofenac sodium 3% gel, calcitriol 3µg/g 4 
ointment and a combination of both in superficial (sBCC) and nodular (nBCC). 5 
Methods Patients with a primary, histologically proven sBCC (n=64) or nBCC (n=64) were randomized 6 
to topical diclofenac, calcitriol, combination of both or no topical treatment (control group). After 7 
self-application twice daily under occlusion (8 weeks), tumors were excised. Primary outcome: post-8 
treatment expression levels of proliferation (Ki-67) and anti-apoptosis (Bcl-2) immunohistochemical 9 
markers. Secondary outcomes: histological clearance, adverse events, application-site reactions, 10 
patient compliance. 11 
Results sBCCs treated with diclofenac showed a significant decrease in Ki-67 (p< 0.001) and Bcl-2 12 
(p=0.001), and after combination therapy for Ki-67 (p=0.012). Complete histological tumor regression 13 
was seen in 64.3% (P=0.0003) of sBCCs (diclofenac) and 43.8% (P=0.007) of sBCCs (combination 14 
therapy) compared to 0.0% of controls. No considerable changes were found in nBCCs. Application-15 
site reactions were mostly mild to moderate. 16 
Limitations The small sample size. 17 
Conclusion Our results suggest that topical diclofenac is a promising new treatment for sBCC. Its 18 
mode of action differs from available non-invasive therapies, and thus has an additive value. 19 
20 
21 
22 
23 
24 
25 
© <2016>. This manuscript version is made available under the CC-BY-NC-ND 4.0 license 
http://creativecommons.org/licenses/by-nc-nd/4.0/ 
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Introduction  26 
Non-melanoma skin cancer (NMSC) is the most common cancer among Caucasians. Sporadic basal 27 
cell carcinoma (BCC) accounts for 80% of all NMSCs and nodular (nBCC) (40%) and superficial BCC 28 
(sBCC) (18-31%), are generally considered to be low-risk tumors.1 Surgical excision, the gold standard 29 
treatment, has cure rates of 95-98%.2, 3 However, because of better cosmetic outcome and lower 30 
healthcare costs, non-invasive treatment modalities such as photodynamic therapy (PDT), imiquimod 31 
(immune-modulating) and 5-fluorouracil cream (chemotherapeutic) are frequently prescribed, for 32 
sBCCs4 with tumor-free survival rates of respectively 72.8-84.0% , 83.4-87.3% and 80.1%.4, 5  33 
Current research on BCC focuses on treatments that specifically target key signaling pathways 34 
required for tumor growth. The Sonic Hedgehog (SHH) signaling pathway is involved in the 35 
pathogenesis of essentially all sporadic BCCs6 and crosstalk with canonical Wingless (WNT) signaling 36 
is described.7 Both SHH and WNT pathways can either directly or indirectly serve as therapeutic 37 
targets for non-steroidal anti-inflammatory drugs (NSAIDs) and the active form of vitamin D (calcitriol 38 
(1α,25[OH]2 D3)) (fig 1). NSAIDs were found to inhibit canonical WNT signaling in patients with 39 
familial adenomatous polyposis and are suggested to be pro-apoptotic in BCC cell lines in a cyclo-40 
oxygenase-2 (COX-2) dependent and independent manner (fig 1).8-10 COX-2 is highly expressed in 41 
several solid tumors, including BCC.11 In a phase II clinical trial, systemic NSAIDs reduced both the 42 
number and burden of BCCs in patients with basal cell nevus syndrome.12 Topically applied diclofenac 43 
induced a clinical response in the majority of the patients with actinic keratosis, which can be a 44 
precursor of squamous cell carcinoma.13 Calcitriol has anti tumour effects in model systems of 45 
several human malignancies derived from prostate, ovary and lungs, which are mainly attributed to 46 
stimulation of the vitamin D receptor (VDR).14 In keratinocytes, the VDR has a regulatory role in SHH 47 
and WNT signaling by acting as a tumor suppressor, reducing proliferation and differentiation and 48 
inducing apoptosis (fig 1).14 49 
We investigated the efficacy of topical application of a NSAID, a vitamin D analogue and the 50 
combination on low-risk BCCs, by evaluating the effects on proliferation and apoptosis. Both well-51 
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accepted drugs are already available for other indications.8 We hypothesized that simultaneously 52 
targeting different signaling pathway elements may have a synergistic effect as suggested by several 53 
preclinical and clinical studies.15 54 
 55 
  56 
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Methods 57 
Protocol 58 
In this phase II, single-blind, randomized-controlled intervention trial, patients from the dermatology 59 
outpatient clinic of the Maastricht University Medical Centre (MUMC), Maastricht, the Netherlands, 60 
were included between November 1st 2011 and February 15th 2013. Histologically proven primary 61 
sBCCs or (micro) nodular BCCs ≥ 4mm, not located in the face or on the hairy scalp, were eligible for 62 
inclusion and were asked to participate in the trial. Mixed sBCC and nBCC were categorized according 63 
to the most aggressive component (nBCC). Patients using oral NSAIDs more than four days a week 64 
(chronic users)16 or vitamin D (containing) supplements in the preceding 30 days were excluded. The 65 
local medical ethics and scientific committee approved the protocol and two following amendments. 66 
The study was performed in accordance with the Declaration of Helsinki. All participants provided 67 
written informed consent. 68 
Enrolled patients with a sBCC or nBCC were randomly assigned to receive either topical diclofenac 69 
sodium-3% gel in hyaluronic acid 2·5% (Solaraze®, Almirall, Barcelona, Spain), calcitriol ointment 3 70 
µg/g (Silkis®, Galderma, Rotterdam, the Netherlands) (henceforward called diclofenac and calcitriol 71 
respectively), a combination of both (combination therapy), or no medication (control group). 72 
The primary outcome measure was the post-treatment percentage of cells expressing the 73 
immunohistochemical stains Ki-67 and Bcl-2. Ki-67, a proliferation marker, can be detected in the 74 
nuclei of proliferating cells. The proto-oncogene Bcl-2, regulating apoptosis, is overexpressed in most 75 
BCC.17 Secondary outcomes were histological tumor regression, adverse events, application-site 76 
reactions and patient compliance. 77 
 78 
Assignment and masking 79 
Randomization via a computer-generated random allocation scheme was stratified for histological 80 
tumor type. Random permuted blocks of eight were used to ensure concealment of allocation. 81 
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Although patients and investigators were not blinded for assigned treatment, the pathologists who 82 
assessed expression levels of Ki-67 and Bcl-2 and histological tumor regression were. 83 
 84 
Participant flow and follow-up 85 
The investigators provided the study medication directly after randomization. The patients applied 86 
the vehicle on the tumor with a radius of 0.5cm and covered it with an occlusive sheet (Tegaderm®, 87 
3M, Leiden, The Netherlands) twice a day for eight weeks. This period was generally the time 88 
patients waited for surgical excision. In case of combination therapy, diclofenac gel application was 89 
followed by calcitriol ointment with a two-minute interval. Treatment was continued until the day 90 
before surgery. In case of a severe local skin reaction, surgery was postponed. Surgical excision was 91 
performed with a 3-5mm safety margin. Expression of Ki-67 and Bcl-2 was evaluated in both baseline 92 
biopsies and excision specimens. No study related follow-up visits were planned after surgical 93 
excision 94 
Treatment reactions were evaluated by a phone interview two weeks after the start of the 95 
treatment. Secondary outcome parameters collected from a diary patients completed once a week 96 
during the course of the treatment included questions on pain expressed on a visual analogue scale, 97 
local skin reactions and compliance. Standardized photographs of all lesions were taken with a ruler 98 
and pantone color card (Danes-Picta, Praha, Czech Republic) on day one and 56. Compliance was 99 
defined as the number of actual applications as a percentage of the total prescribed number of 100 
applications. 101 
 102 
Statistical analysis 103 
We aimed to include 64 nBCC and 64 sBCC patients to enable comparison of the four study arms 104 
separately for sBCC and nBCC. Continuous variables were presented as a mean with ± standard 105 
deviations (if normally distributed) or as a median with an interquartile range (if not normally 106 
distributed). Differences in proportions between groups were tested using the Fisher’s exact test. 107 
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Analysis of covariance (ANCOVA) was used to compare post-treatment expression of Ki-67 and Bcl-2 108 
between treatment groups and control group. Variables indicating treatment group and baseline 109 
expression levels of Ki-67 and Bcl-2 were entered as independent variables. The regression 110 
coefficients associated with the treatment groups represent the difference in post-treatment 111 
expression level between the corresponding treatment group and the control group. In case of 112 
skewed baseline distributions of the of Ki-67 and Bcl-2 expression levels data were log transformed 113 
to normalize distributions and normality of the distribution of residuals was checked using a normal 114 
probability plot. Statistical analyses were carried out using SPSS 20.0 software and 115 
www.openepi.com. All reported P values are two-sided, and P values ≤0.05 were considered 116 
statistically significant. This study is registered as a controlled trial at clinicaltrials.gov, number 117 
NCT01358045, since May 17th 2011. 118 
 119 
  120 
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Results 121 
Patients 122 
All 128 included patients (64 nBCC and 64 sBCC), were randomly assigned to one of the four study 123 
arms, with equal distribution of the baseline demographics and tumor characteristics (table 1). One 124 
patient withdrew directly after treatment allocation. The primary outcome was not available for 125 
eight patients: one patient had a BCC that required treatment by Mohs’ micrographic surgery, 126 
another patient had a syringoma and for six other patients, the biopsy or excision specimens did not 127 
include sufficient tumor tissue to enable immunohistochemistry for Ki-67 and Bcl-2. Subjects with 128 
missing primary outcome were evenly distributed among the treatment groups. Totally, 119 patients 129 
were included in the statistical analysis of the primary outcome (n=59 sBCC and n=60 nBCC, ). No 130 
crossovers occurred. 131 
 132 
Immunohistochemical analysis of proliferation and apoptosis 133 
Figure 2 illustrates the median expression levels of Ki-67 and Bcl-2 in tumor cells before and after 134 
treatment for sBCC and nBCC in the four randomized groups. With respect to sBCCs, this figure 135 
shows that in the control group median values of endpoint Ki-67 expression levels increased slightly 136 
when compared with baseline levels. There was a substantial decrease in Ki-67 expression after 137 
treatment with diclofenac and combination therapy and a small increase in the calcitriol group. 138 
Median values in Bcl-2 expression show a small increase in the control group, whereas there was a 139 
slight decrease in tumors treated with diclofenac, calcitriol and combination treatment.  140 
The distributions of Ki-67 and Bcl-2 expression levels were skewed and a log(x+1) transformation was 141 
used to normalize the distributions. ANCOVA analyses were used to adjust for imbalances in baseline 142 
values of Ki-67 and Bcl-2. The mean differences between the treatment groups and the control group 143 
were back transformed from the logarithm scale to raw scale and are presented in Table 2. Ki-67 144 
expression was significantly lower in sBCCs treated with diclofenac and combination therapy, when 145 
compared to the post treatment levels in the control group(p <0.001 and p=0.012, respectively, table 146 
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2). Also, Bcl-2 expression was significantly lower in sBCCs treated with diclofenac (p=0.001, table 2). 147 
Post treatment expression levels in sBCCs treated with calcitriol and in all nBCCs did not differ 148 
significantly from those in the control group, neither for Ki-67 nor for Bcl-2 (Table 2).  149 
 150 
Clinical response and compliance 151 
In the sBCC subgroup, histologically complete tumor regression was seen in 64.3% (9 of 14) and in 152 
43.8% (7 of 16) of the tumors treated with diclofenac and combination therapy respectively (fig 3). 153 
The difference with the control group (0 of 16) was statistically significant (P=0.0003 and P=0.007, 154 
respectively). None of the participants in the calcitriol group showed complete regression. In the 155 
nBCC subgroup 31.2% (5 of 16), 6.2% (1 of 16), 33.3% (5 of 15) showed histological complete 156 
regression in patients treated with diclofenac, calcitriol or combination therapy, respectively. No 157 
residual tumor was observed in 18.8% (3 of 16) of the nBCC control group (fig 3). Differences 158 
between active treatment groups and the control group were not statistically significant. 159 
In the sBCC subgroup with no complete tumor regression, a nodular BCC component was found in 160 
four tumors assigned to the combination therapy group. In the calcitriol group two tumors with a 161 
nodular, and one with an invasive component were found.  162 
Median compliance rates were generally high (92.7%-98.2%) and comparable between groups 163 
(n=95). 164 
 165 
Adverse events 166 
Adverse events were mostly mild to moderate. Erythema, pruritus and erosions at the target tumor 167 
site were most frequently reported (table 3). In eight cases the severity of the application-site 168 
reactions led to discontinuation of the therapy and prescription of a topical antimicrobial cream. In 169 
19.4% (6 of 31) of patients treated with diclofenac and 9.4% (3 of 32) of patients treated with 170 
combination therapy, surgical excision was postponed two weeks, due to the severity of application-171 
site reactions. Three patients had serious adverse events requiring hospitalization (table 3), but none 172 
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of these serious adverse events were considered to be related to the study medication. No adverse 173 
events were reported in the control group.                                                                                                                                                                                                                                                                                                                  174 
 175 
  176 
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Discussion  177 
This phase II trial provides evidence that topical diclofenac has the potential to clear sBCC, with 178 
complete histologic tumor regression in 64.3% (9 of 14) and 43.8% (7 of 16) of the patients treated 179 
with diclofenac and combination therapy, respectively. These results are in line with significant 180 
decreases of expression levels of the proliferative marker Ki-67 and the anti-apoptotic marker Bcl-2 181 
in these treatment groups. Although, application-site reactions were reported frequently, most 182 
reactions were of mild to moderate severity, which is in accordance with the literature.18 Similar 183 
reactions are seen in other non-invasive therapies for sBCC, such as imiquimod and 5-fluorouracil 184 
cream and probably necessary to achieve tumor regression.2, 4 Occlusion may have attributed to the 185 
severity of the skin reactions. 186 
There was no clinical effectiveness of calcitriol. In calcitriol treated sBCCs, slight increases in 187 
expression levels of the proliferative marker Ki-67 and slight decreases in the anti-apoptotic marker 188 
Bcl-2 were detected, which were not statistically significant. We found no evidence for the 189 
hypothesized synergistic effect of the combination of diclofenac and calcitriol. The observed clinical 190 
effect of the combination therapy in sBCC is probably due to the effect of diclofenac, but lower 191 
following dilution by the calcitriol. A relatively high ratio of nodular BCC components in tumors 192 
diagnosed as sBCC, also found in other studies, is also a possible explanation for lower efficacy.  193 
In the nBCC subgroup, no significant effects of treatment on Ki-67 and Bcl-2 expression levels or in 194 
histological tumor clearance were found. However, when comparing post treatment expression 195 
levels of Ki-67 between the calcitriol and the control group (fig 2), calcitriol treated nBCCs had even 196 
slightly higher Ki-67 and Bcl-2 expression. Previous in vitro studies found that high doses of calcitriol 197 
can inhibit keratinocyte proliferation, while lower doses may stimulate proliferation.19, 20 Also, topical 198 
application of low dose calcitriol to mouse skin can stimulated epidermal proliferation21, which might 199 
explain our findings in nBCC. 200 
11 
 
 
 
Excipients such as hyaluronic acid may enhance the penetrance and bioavailability of a substance.22 201 
Whereas the diclofenac sodium-3% gel contains 2.5% hyaluronic acid, calcitriol does not. Possibly, a 202 
higher concentration of calcitriol and/or a different vehicle might be needed. 203 
Complete tumor regression was seen in 18.8% of the controls in the nBCC subgroup. As we included 204 
tumors ≥ 4mm and punch biopsies were 3mm, total tumor clearance could be a result of a biopsy-205 
induced local immune response23, or a lack of sensitivity of regular histological techniques to detect 206 
small amounts of residual tumor. “Therapeutic biopsy”, could have occurred in all other treatment 207 
groups and underlines the importance of a control group. In other studies the response on non-208 
invasive therapies also differs between nBCC and sBCC and is presumably caused by insufficient 209 
penetration of the drug into the deeper dermis.24  210 
The clinical effectiveness of diclofenac was not as high as that of currently available non-invasive BCC 211 
treatments. However, the ability to attack different molecular pathways activated in BCC is an 212 
important finding. Evidence has already suggested that simultaneously targeting SHH and other 213 
signaling pathways may have a synergistic effect.15 Combination of therapies is therefore a logical 214 
next step in improving topical treatments. Combining diclofenac with imiquimod cream could be 215 
promising, as imiquimod is known to inhibit the SHH-pathway25 and is currently the most effective 216 
non-invasive therapy for BCC. However, with a 1-year efficacy of 83.4%26, it is still not as effective as 217 
surgery. By adding a drug targeting a different pathway, such as diclofenac cream, the imiquimod 218 
resistant cells could be attacked, resulting in higher long-term cure rates. 219 
Limitations of the study are the small sample size and imbalances in baseline levels of Ki-67 and Bcl-2 220 
Despite the small sample size, significant effects of diclofenac treatment in targeting key signaling 221 
pathways could be demonstrated and ANCOVA was used to adjust for the differences in baseline 222 
levels.  223 
This trial provides evidence that topical application of diclofenac 3% gel in 2.5% hyaluronic acid in 224 
sBCC significantly reduces proliferation, induces apoptosis and moreover results in significant 225 
histological clearance compared to the control group. We therefore conclude that although surgical 226 
12 
 
 
 
excision remains the gold standard for all BCC, topical diclofenac may be a promising new treatment 227 
for low risk sBCC. Efficacy of topical calcitriol was not observed. Other trials using different 228 
concentrations, excipients or combinations of both investigated drugs may be useful to optimize 229 
treatment strategies. Also, given the effectiveness of diclofenac gel in treatment of both BCCs and 230 
actinic keratosis with only limited side effects, the role for topical diclofenac as a prophylactic agent 231 
in NMSC is an interesting subject for future studies.  232 
  233 
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Figure legends 
 
Figure 1. Actions of NSAIDs and Calcitriol in Basal Cell Carcinoma: a schematic overview. 
Sonic Hedgehog Pathway (green). The extracellular protein Sonic hedgehog (SHH) binds to and 
inhibits Patched (PTCH1), a transmembrane receptor, which relieves the inhibition of another 
transmembrane protein, Smoothened (SMO). SMO activates glioma-associated oncogene homolog 1 
(GLI1) and GLI2, transcription factors that travel into the nucleus to activate the expression of tumor-
promoting genes.6 Canonical WNT signaling pathway (pink). Binding of a WNT ligand to its specific 
receptor complex containing a Frizzled (FZD) family member and LRP5 or LRP6 co-receptors, initiates 
WNT-β-catenin signaling. Axin relocates to the LRP 5/6 tail at the membrane that is bound to WNT 
through its interaction with dishevelled (DVL), which forms a complex with GSK3β and prevents β-
catenin (β-cat) degradation.8 This allows β-catenin to accumulate and enter the nucleus, where it 
interacts with members of the TCF/LEF family. In the nucleus, β-catenin converts the TCF proteins 
into transcriptional activators. Suppressor of fused (SUFU) functions as a tumor suppressor by 
inhibiting both SHH and WNT signaling.7 
NSAIDs inhibit WNT signaling by reducing nuclear β-catenin localization.8, 27 Furthermore, NSAIDs 
inhibit cyclo-oxygenase-2 (COX-2), which is overexpressed in basal cell carcinoma (BCC) and catalyzes 
the conversion of arachidonic acid (AA) to prostaglandins (PGE2). A subsequent reduction of PGE2 
and a direct down regulation of the anti-apoptotic Bcl-2 family proteins by NSAIDs induces 
apoptosis.9 A down regulation of Bcl-2 is also induced by 1α,25(OH)2D3 (calcitriol), resulting in 
caspase cleavage leading to apoptosis. Calcitriol directly inhibits SMO in vitro, resulting in repression 
of SHH signaling. SHH-signaling is also suggested to be directly repressed by the Vitamin D Receptor 
(VDR) by inhibition of GLI. Finally, activation of the VDR by calcitriol induces the expression of the 
transmembrane protein E-Cadherin, which recruits β-catenin to the cell membrane and prevents 
translocation of β-catenin to the nucleus.14, 28, 29 
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Figure 2: Pre- versus post-treatment scatterplot of changes in Ki-67 and Bcl-2 expression.  
Data are median %. Abbreviation: BCC=Basal Cell Carcinoma. Diclofenac=diclofenac sodium-3% gel, 
Calcitriol=calcitriol 3µg/g ointment, Combination therapy=diclofenac and calcitriol. Pre- versus post-
treatment changes in Ki-67 and Bcl-2 expression after 8 weeks treatment according to treatment 
groups.  
 
Figure 3: Complete histologic tumor regression rates after 8 weeks of topical treatment. 
Abbreviation: BCC=Basal Cell Carcinoma. Diclofenac=diclofenac sodium‐3% gel, Calcitriol=calcitriol 
3μg/g ointment, Combination therapy=diclofenac and calcitriol. P‐values were calculated with Fisher 
exact test. Complete histologic tumor regression for superficial BCC and for nodular BCC according to 
treatment groups, compared to control group. 
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Abbreviations:  
BCC, basal cell carcinoma 
sBCC, superficial basal cell carcinoma 
nBCC, nodular basal cell carcinoma 
SHH, Sonic Hedgehog 
SMO, Smoothened 
NSAIDs, non-steroidal anti-inflammatory drugs 
VDR, vitamin D receptor. 
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